Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
14 May 2012Website:
http://www.avitamedical.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | 7 min agoDividend
Analysts recommendations
Institutional Ownership
RCEL Latest News
VALENCIA, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced the appointment of Nicole Linda Kelsey as Chief Legal and Compliance Officer, and Corporate Secretary, effective July 1, 2024.
VALENCIA, Calif., June 05, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the Joseph M.
VALENCIA, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that the U.S. Food and Drug Administration (FDA) has approved its premarket approval (PMA) supplement for the RECELL GO™ System, its next-generation autologous cell harvesting device that harnesses the regenerative properties of a patient's own skin to treat thermal burn wounds and full-thickness skin defects.
AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a regenerative medicine company specializing in wound care devices, is hosting an investor webinar on May 21, 2024, at 4:00 p.m. featuring CEO Jim Corbett and CFO David O'Toole. Shareholders and potential investors are encouraged to attend.
AVITA Medical will announce its financial results for the first quarter of 2024 on May 13, 2024, after the market closes. A webcast will be hosted at 1:30 p.m. Pacific Time on the same day.
AVITA Medical, Inc. (RCEL) Q4 2023 Earnings Call Transcript
VALENCIA, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices and autologous cellular therapies for skin restoration, today announced that it will report its fourth quarter and full year 2023 financial results after the close of the U.S. financial markets on Thursday, February 22, 2024.
AVITA Medical's Spray-On Skin Cells device rapidly processes a patient's own skin to treat large dermatological injuries. The company's sales growth is expected to accelerate in 2024 due to the supplement of its RECELL System for full-thickness skin defects. AVITA's expanded FDA label approval has significantly increased its addressable market, with an opportunity in excess of $2.7 billion in the US alone.
Avita's (RCEL) stock declines 19% after the company lowered its total revenue guidance for 2023.
AVITA Medical, Inc. (NASDAQ:RCEL ) Q3 2023 Results Conference Call November 9, 2023 4:30 PM ET Company Participants Jessica Ekeberg - Director of Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Joshua Jennings - Cowen Brooks O'Neil - Lake Street Capital Markets John Hester - Bell Potter Ross Osborne - Cantor Fitzgerald Madeline Williams - Wilsons Operator Good day, and thank you for standing by. Welcome to the AVITA Medical Third Quarter 2023 Earnings Call.
- 1(current)
What type of business is AVITA Medical?
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
What sector is AVITA Medical in?
AVITA Medical is in the Healthcare sector
What industry is AVITA Medical in?
AVITA Medical is in the Medical Devices industry
What country is AVITA Medical from?
AVITA Medical is headquartered in United States
When did AVITA Medical go public?
AVITA Medical initial public offering (IPO) was on 14 May 2012
What is AVITA Medical website?
https://www.avitamedical.com
Is AVITA Medical in the S&P 500?
No, AVITA Medical is not included in the S&P 500 index
Is AVITA Medical in the NASDAQ 100?
No, AVITA Medical is not included in the NASDAQ 100 index
Is AVITA Medical in the Dow Jones?
No, AVITA Medical is not included in the Dow Jones index
When does AVITA Medical report earnings?
The next expected earnings date for AVITA Medical is 09 August 2024